324 filings
8-K
SKYE
Skye Bioscience Inc
10 Jun 24
Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program
9:27am
EFFECT
SKYE
Skye Bioscience Inc
20 May 24
Notice of effectiveness
12:15am
EFFECT
SKYE
Skye Bioscience Inc
20 May 24
Notice of effectiveness
12:15am
424B3
SKYE
Skye Bioscience Inc
17 May 24
Prospectus supplement
4:27pm
S-3
SKYE
Skye Bioscience Inc
Shelf registration
10 May 24
4:19pm
EFFECT
adf8o5
29 Apr 24
Notice of effectiveness
12:15am
POS AM
n1cmpz
24 Apr 24
Prospectus update (post-effective amendment)
4:40pm
EFFECT
2xgzg3czgc g067q4s3
11 Apr 24
Notice of effectiveness
12:15am
424B3
9ty76tzjp8nad1mn
10 Apr 24
Prospectus supplement
4:40pm
CERT
3xa1e9973wp gr5c8wq
10 Apr 24
Certification of approval for exchange listing
9:58am
8-A12B
atcgp4rjs
10 Apr 24
Registration of securities on exchange
7:00am
8-K
or89vd
3 Apr 24
Regulation FD Disclosure
5:07pm
D
b5qgt6am1 oq5o
26 Mar 24
$40.00 mm in equity, sold $40.00 mm, 13 investors
6:04pm
8-K
37duhs47b4j uhv
13 Mar 24
Entry into a Material Definitive Agreement
4:13pm
8-K
d4w4jvsx
4 Mar 24
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
4:23pm